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The gut microbiota suppresses insulin-mediated
fat accumulation via the short-chain fatty acid
receptor GPR43
Ikuo Kimura1,*, Kentaro Ozawa2,*, Daisuke Inoue1,*, Takeshi Imamura3, Kumi Kimura4, Takeshi Maeda1,
Kazuya Terasawa1, Daiji Kashihara1, Kanako Hirano1, Taeko Tani1, Tomoyuki Takahashi1, Satoshi Miyauchi1,
Go Shioi5, Hiroshi Inoue4 & Gozoh Tsujimoto1,6
The gut microbiota affects nutrient acquisition and energy regulation of the host, and can
influence the development of obesity, insulin resistance, and diabetes. During feeding, gut
microbes produce short-chain fatty acids, which are important energy sources for the host.
Here we show that the short-chain fatty acid receptor GPR43 links the metabolic activity of
the gut microbiota with host body energy homoeostasis. We demonstrate that GPR43-
deficient mice are obese on a normal diet, whereas mice overexpressing GPR43 specifically in
adipose tissue remain lean even when fed a high-fat diet. Raised under germ-free conditions
or after treatment with antibiotics, both types of mice have a normal phenotype. We further
show that short-chain fatty acid-mediated activation of GPR43 suppresses insulin signalling in
adipocytes, which inhibits fat accumulation in adipose tissue and promotes the metabolism of
unincorporated lipids and glucose in other tissues. These findings establish GPR43 as a
sensor for excessive dietary energy, thereby controlling body energy utilization while main-
taining metabolic homoeostasis.
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T
he gut microbiota is an assortment of microorganisms
inhabiting the mammalian gastrointestinal tract, and
recent research has demonstrated that the gut microbiota
is involved in obesity and metabolic disorders1–4. Studies using
high-fat diet (HFD)-induced obesity-related mice have linked an
altered gut microbiota composition to the development of obesity,
insulin resistance and diabetes in the host through several
mechanisms, including increased energy harvest from the diet
and altered fatty acid metabolism and composition in the adipose
tissue and liver5–8.
One important activity of the gut microbiota is to catabolize
dietary fibres that are not completely hydrolysed by host
enzymes9. The main colonic bacterial fermentation products of
dietary fibre are short-chain fatty acids (SCFAs) such as acetate,
propionate and butyrate10; SCFAs can be utilized for de novo
synthesis of lipids and glucose11, which are used as the main
energy sources for the host.
In addition to energy sources, SCFAs have been established as
essential nutrients that also act as signalling molecules. Recently,
two orphan G protein-coupled receptors, GPR41 and GPR43,
have been reported to be activated by SCFAs12. GPR41 has been
reported to couple to Gi/o as a-subunit of heterotrimeric
G protein and act as a gut microbiota-related energy sensor in
the sympathetic nervous system and the intestines13–16. GPR43
reportedly couples to either Gi/o or Gq as another a-subunit of
heterotrimetric G protein17,18. GPR43 has also been reported to
be expressed in the adipose tissue, intestines and immune
tissues19,20. In the immune system, regulation of inflammatory
responses by GPR43 is a well-studied process20–22; however,
GPR43 has not been as well studied in the adipose tissue. Some
studies have indicated that GPR43 promotes leptin secretion,
adipogenesis and inhibition of lipolysis in adipose tissue and
adipocytes, thereby regulating energy metabolism19,23,24. HFD-
fed GPR43-deficient mice exhibit improved glucose tolerance and
reduced body fat mass25. On the other hand, other group
reported that GPR43 expressed in the intestine improves glucose
tolerance by promoting the secretion of glucagon-like peptide-1
(GLP-1; such as incretin) from L cells26.
The roles of GPR43 in metabolic processes are still unclear. In
this study, using mice lacking GPR43 and with adipose-specific
overexpression of GPR43, we present the true function of GPR43
in the adipose tissue and the role of GPR43 in the regulation of
the energy balance.
Results
Gpr43 is abundantly expressed in the white adipose tissue.
Gpr43 was mainly expressed in the immune tissue and the white
adipose tissue (WAT) of adult mice, as previously reported18,19,
but not in the brown adipose tissue (BAT; Fig. 1a). In situ
hybridization at the postnatal stage (P1) confirmed that Gpr43
was most abundantly expressed in the WAT and was not
expressed in the BAT (Fig. 1b). During adipogenesis, Gpr43 was
expressed in the later stages of differentiation than aP2 and
PPARg, markers of mature adipocytes (MAs) in 3T3-L1 pre-
adipocytes and mouse embryonic fibroblasts (MEFs; Fig. 1c). In
the adult mouse adipose tissue, Gpr43 was abundantly expressed
in the MA fraction but not in the stromal vascular fraction,
containing pre-adipocytes and macrophages (Fig. 1d). Moreover,
Gpr43 expression was markedly higher in the WAT of HFD-fed
mice as compared with normal chow (NC)-fed mice (Fig. 1e).
Thus, Gpr43 was abundantly expressed in the mature WAT but
not in the BAT or in pre-adipocytes.
Gpr43 knockout mice exhibit obesity. To clarify the function
of GPR43 in the WAT, we generated Gpr43 / mice
(Supplementary Fig. S1a–d). The Gpr43 / mice showed no
difference in the WAT area compared with wild-type mice at the
embryonic stage (P1; Fig. 2a), indicating that GPR43 had no effect
on adipocyte differentiation. However, the body weights and
WAT weights of both NC- and HFD-fed Gpr43 / mice were
significantly higher than that of wild-type mice during growth
(Fig. 2b,c). Differences in the body weight between wild-type and
Gpr43 / mice were enhanced in an HFD-fed condition. The
food intake was comparable between wild-type and Gpr43 /
mice fed an NC but was higher in Gpr43 / mice fed an HFD
(Supplementary Fig. S2a). In contrast, the plasma leptin levels
were similar between wild-type and Gpr43 / mice fed an
HFD (Supplementary Fig. S2b). A significant increase in adipo-
cyte size in WAT (Fig. 2d), but not BAT (Supplementary
Fig. S2c), was also observed in HFD-fed Gpr43 / mice.
Furthermore, messenger RNA and protein expression of aP2 and
PPARg were enhanced in the WAT of HFD-fed Gpr43 /
mice (Fig. 2e,f), while mRNA expression of PPARg and UCP1, a
thermogenesis marker, in the BAT was not significantly changed
(Supplementary Fig. S2d). Moreover, HFD-induced insulin
resistance, as determined by insulin tolerance test (ITT) and
glucose tolerance test (GTT), was significantly increased in
Gpr43 / mice, compared with wild-type mice, whereas they
were no differences in NC-fed mice (Fig. 2g,h). During insulin
clamp studies, the glucose infusion rate (GIR) required to
maintain euglycaemia, glucose rate of disappearance (Rd) and
suppression of hepatic glucose production (HGP) were sig-
nificantly decreased in HFD-fed Gpr43 / mice compared
with HFD-fed wild-type mice (Fig. 2i). Thus, these results indi-
cate the decreased insulin sensitivity in HFD-fed Gpr43 /
mice. Furthermore, HFD-fed Gpr43 / mice exhibited an
increase in F4/80-positive macrophages, compared with HFD-fed
wild-type mice (Fig. 2j, left panel). The expression of F4/80
(Fig. 2j, middle panel) and the inflammatory marker gene TNFa
(tumour necrosis factor a) (Fig. 2j, right panel) in both NC- and
HFD-fed Gpr43 / mice markedly increased, compared with
wild-type mice. Thus, Gpr43 / mice showed progression of
inflammation accompanying the obese phenotype.
We next examined the effects of the gut microbiota in the
WAT. Communities of gut microbiota in Gpr43 / mice
exhibited an increase in Firmicutes, an SCFA-producing phylum,
and a decrease in g-proteobacteria and actinobacteria (Fig. 2k).
Faecal SCFA and plasma acetate concentrations in Gpr43 /
mice increased compared with wild-type mice (Fig. 2l,m).
Treatment with antibiotics lowered the total gut microbiota load
by 90% and caused enlargement of the ceca (Supplementary
Fig. S2e), similar to observation in germ-free (GF) mice27, then
faecal SCFAs were markedly decreased (Supplementary Fig. S2f).
Plasma acetate decreased significantly by antibiotic treatment and
under GF conditions, which was recovered by returning to
conventional (CONV) conditions (Supplementary Fig. S2g).
Interestingly, differences in the body weights and WAT weights
between HFD-fed Gpr43 / and wild-type mice were
completely abolished under GF conditions (Fig. 2n (left panel)
and 2o). The difference could be observed again after returning to
CONV conditions (Fig. 2n (right panel) and 2o). Moreover,
under antibiotic treatment, the difference in insulin resistance of
wild-type and Gpr43 / mice by ITT and GTT was abolished
(Fig. 2p,q). During feeding, the acetate level was increased after
the rise in glucose, which was completely abolished by treatment
with antibiotics (Fig. 2r). We found that administration of acetate
during antibiotic treatment recovered the plasma acetate levels to
that under normal conditions (Supplementary Fig. S2g). In
addition, the body weight and WAT weight decreased signi-
ficantly by administration of acetate with antibiotic treatment in
wild-type mice, whereas these effects were not exhibited in
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Gpr43 / mice (Fig. 2s,t). These results suggested that the
GPR43 function is closely linked with the SCFAs produced by the
gut microbiota.
Adipose-specific Gpr43 transgenic mice are lean. To determine
whether the obesity in Gpr43 / mice was due to the defi-
ciency of GPR43 in the adipose tissue and not in the immune
system and the intestines, we generated aP2 promoter-driven
adipose-specific Gpr43 transgenic mice (aP2-Gpr43TG;
Supplementary Fig. S1e–h). Similar to Gpr43 / mice, aP2-
Gpr43TGmice also showed no difference in the WAT area during
adipogenesis, as compared with wild-type mice at the embryonic
stage (P1; Fig. 3a). On the other hand, the body weights and
WAT weights of aP2-Gpr43TG mice were significantly lower than
those of wild-type mice during growth (Fig. 3b,c). However, while
the food intake was comparable (Supplementary Fig. S2h), the
plasma leptin level was significantly reduced in aP2-Gpr43TG
mice compared with wild-type mice (Supplementary Fig. S2i).
The adipocyte size in the WAT of aP2-Gpr43TG mice was sig-
nificantly smaller than that of wild-type mice (Fig. 3d). Further-
more, the mRNA and protein expression of aP2 and PPARg
decreased in the WAT of aP2-Gpr43TG mice (Fig. 3e,f). Com-
pared with the alterations observed in Gpr43 / mice, com-
munities of gut microbiota were not dramatically different
between wild-type and aP2-Gpr43TG (Fig. 3g); however, faecal
SCFA and plasma acetate concentrations in aP2-Gpr43TG mice
were higher compared with those in wild-type mice (Fig. 3h,i).
These data indicate that the alteration of gut microbiota com-
munities observed in Gpr43 / mice is not dependent on the
function of GPR43 expressed in adipose tissues; however, GPR43
in other tissues, such as the immune system, maybe involved in
this alteration. Differences in the body weight and WAT weight
between wild-type and aP2-Gpr43TG mice were also completely
abolished by antibiotic treatment (Fig. 3j,k).
Next, we examined the effects of overexpressing GPR43 in the
WAT on HFD-induced obesity. Increases in the body weight,
WAT weight and blood glucose by HFD-induced obesity were
markedly suppressed in aP2-Gpr43TG mice (Fig. 3l–n). More-
over, HFD-induced insulin resistance, as determined by ITT and
GTT, was significantly attenuated in aP2-Gpr43TG (Fig. 3o,p).
During insulin clamp studies, in contrast to Gpr43 / mice,
the GIR, Rd and HGP suppression in HFD-fed aP2-Gpr43TG
mice were significantly increased, compared with HFD-fed wild-
type mice (Fig. 3q). Moreover, under antibiotic treatment, the
difference in insulin resistance of wild-type and aP2-Gpr43TG
mice was attenuated (Fig. 3r,s). HFD-induced obesity caused liver
steatosis and high hepatic triglyceride content in wild-type mice
but not in aP2-Gpr43TG mice (Fig. 3t). Furthermore, HFD-fed
aP2-Gpr43TG mice exhibited a decrease in F4/80-positive macro-
phages, compared with HFD-fed wild-type mice (Fig. 3u, left
panel) and the expression of F4/80 (Fig. 3u, middle panel) and
TNFa (Fig. 3u, right panel) in aP2-Gpr43TG mice was decreased.
On the basis of the data for aP2-Gpr43TG mice, we concluded
that progression of inflammation in KO mice was mainly caused
by obesity; however, we do not exclude the possibility that dele-
tion of GPR43 in the immune system enhances inflammation in
WAT. These results showed that overexpressing GPR43 sup-
pressed HFD-induced obesity and improved insulin sensitivity.
GPR43 suppresses insulin signalling in adipose tissue. We
further examined the relationship between GPR43 function and
insulin sensitivity. The WAT, muscles and liver are the three
major tissues involved in fuel metabolism28. Surprisingly,


























































































































































Figure 1 | Gpr43 is abundantly expressed in the WATs. (a) Gpr43 expression in postnatal mouse tissues (P49) measured by qRT-PCR (n¼ 3). Internal
control: 18S rRNA expression. (b) Gpr43 mRNA localization in mouse embryos (P1) as determined by in situ hybridization using an 35S-labelled antisense
Gpr43 RNA probe. Black grains superimposed on haematoxylin eosin (H&E) and oil red O-stained sections indicate Gpr43 mRNA localization. Arrow
indicates WAT; arrowhead indicates BAT. Scale bar, 1mm. (c) Expression of Gpr43 mRNA during differentiation. MEF and 3T3-L1 pre-adipocytes were
induced to differentiate in the presence of MDI. Total RNA was analysed by RT-PCR. 18S was used as a loading control. (d) Gpr43 expression in stromal
vascular fraction (SVF) and MAs measured by qRT-PCR (n¼ 3). 18S was used as a loading control. (e) Gpr43 expression in the WAT of NC and HFD-fed
mice measured by qRT-PCR (n¼4); 18S was used as a loading control. Mice were analysed at 16 weeks of age (d, e). All data are presented as
mean±s.e.m. Student’s t-test; *Po0.05; **Po0.005. Epi, epididymal; Mes, mesenteric; Per, perirenal; Sub, subcutaneous.
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compared with wild-type mice in the context of HFD feeding
(Fig. 3o,p), insulin-induced Akt phosphorylation in the WAT, but
not the muscles or liver, was markedly suppressed (Fig. 4a–c).
Administration of acetate significantly suppressed insulin-induced
Akt phosphorylation in the WAT, but not the muscles or liver of
wild-type mice, whereas the effect was not exhibited in the WAT
of Gpr43 / mice (Fig. 4d–f). These results indicated that
GPR43 signalling suppressed insulin signalling only in the WAT.
Hence, we next examined the functions of SCFAs and
GPR43 on WAT insulin signalling-related bioactivity29. GPR43
promotes adipogenesis in vitro19. Thus, to avoid variations in the
differentiation of adipocytes by GPR43 deficiency, we used
pioglitazone-induced adipogenesis30. As expected, adipogenesis
in pioglitazone-enhanced MEF-derived adipocytes did not
differ in wild-type and Gpr43 / or aP2-GPR43TG mice
(Supplementary Fig. S3a,b). Acetate significantly suppressed the
insulin-induced glucose and fatty acid uptake in adipocytes
from wild-type mice but not Gpr43 / mice (Fig. 4g,i;
Supplementary Fig. S3c), whereas it was further enhanced in
adipocytes from aP2-Gpr43TG mice (Fig. 4h,j). Moreover,
the lipoprotein lipase (LPL) activity was higher in HFD-fed
Gpr43 / mice, and lower in aP2-Gpr43TG in the WAT but
not in muscle (Fig. 4k,l). These effects on the LPL activity in the
WAT were abolished under GF conditions and by antibiotic
treatment (Fig. 4m). In addition, Lpl mRNA expression in the
WAT was comparable in Gpr43 / mice, and lower in aP2-
Gpr43TG mice (Supplementary Fig. S3d). Collectively, these
results indicated that suppression of insulin signalling in the
WAT, but not the muscles or liver, altered the glucose and lipid
metabolism by acetate-dependent GPR43 stimulation.
GPR43 suppresses insulin signalling via G(i/o)bc–PLC–PKC–
PTEN. We further examined the GPR43-mediated intracellular
signalling in 3T3-L1 pre-adipocyte-derived adipocytes. Phenyla-
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Figure 2 | Gpr43 knockout mice are obese. (a) WATand BATof littermates (P1) were stained with oil red O. Scale bar: 5mm (upper), 100mm (lower). Body
weight (b, n¼ 10, 11) and fat mass (c, n¼ 6–10) changes. Scale bar, 1 cm. (d) Haematoxylin–eosin (H&E)-stained WATand mean area of adipocytes (n¼ 3).
Scale bar, 100mm. Expression of aP2 and Pparg mRNA (e, n¼4) and protein (f) in the WAT of HFD-fed mice. ITT (g, n¼4–6) and GTT (h, n¼ 6, 7).
(i) Euglycaemic hyperinsulinaemic clamp in HFD-fed mice. Left: glucose infusion ratio; middle: glucose disposal rate; right: hepatic glucose production
suppression. Body weights; WT (33±2.9 g): Gpr43 / (39±1.7 g), 14–15 weeks of age (n¼4). (j) Level of inflammation (left panel) and expression of F4/
80 (middle panel, n¼4, 5) and TNFa (right panel, n¼4 6) mRNA in WAT. Scale bar, 100mm. (k) Comparison of microbial communities in HFD-fed mice, as
assessed by qPCR (n¼4). Act, actinobacteria; All, all bacteria; Bact, bacteroidetes; Firm, firmicutes; Prot, g-proteobacteria. (l, m) Faecal major SCFA and
plasma acetate contents in HFD-fed mice (n¼4). Ace, acetate; But, butyrate; Pro, propionate. (n) Body weights of HFD-fed mice under GF conditions (20
weeks) (n¼4, 6) (left panel). Body weight changes under GF to CONV conditions (n¼4–6) (right panel). (o) Fat mass in 18-week-old mice under GF
condition (n¼4, 6) and 22-week-old mice on HFD under CONV conditions after 16 weeks of GF conditions (n¼4, 5). (p, q) ITT and GTT under antibiotic
treatment (n¼4). Abs, antibiotics. (r) Acetate and glucose plasma concentrations after 1 h of feeding (24h fasting) (left panel). Plasma acetate concentration
with or without antibiotic treatment during feeding (right panel) (n¼4). (s, t) Effect of acetate on body weights and fat mass under antibiotic treatment
(n¼ 6). Mice were analysed at 14 or 16 weeks of age. All data are presented as mean±s.e.m. Student’s t-test; *Po0.05; **Po0.005; NS, not significant.
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cyclopropanecarboxylic acid is a partially selective GPR41 agonist
(Supplementary Fig. S4a,b). Acetate and PA significantly
suppressed insulin-induced Akt phosphorylation, whereas
cyclopropanecarboxylic acid weakly suppressed the same
(Fig. 5a). On the other hand, N6-cyclopentyladenosine, a ligand
for the adenosine A1 receptor (Gi/o-type G protein-coupled
receptor)32 had no effects on insulin-induced Akt phosphory-
lation (Supplementary Fig. S4c). GPR43-mediated suppression of
insulin-induced Akt phosphorylation was effectively blocked by
the treatment with pertussis toxin (PTX), a Gi/o-type G protein
inactivator33 (Fig. 5b), whereas the treatment of short interfering
RNA (siRNA) against Gq protein (Supplementary Fig. S4d,e) had
no inhibitory effects (Fig. 5c). Moreover, GPR43-mediated
suppression of insulin-induced Akt phosphorylation was
effectively blocked by the treatment with Gallein (Gbg blocker)
but not NF023 (Ga(i/o) blocker14) (Fig. 5b). It is reported that
G(i/o)bg mediates to the PLC–PKC–ERK pathway34. GPR43-
mediated suppression of insulin-induced Akt phosphorylation
was effectively blocked by the treatment with U73122 (PLC
inhibitor) and Go6983 (PKC inhibitor), but not U0126 (MEK
inhibitor) (Fig. 5d).
Next, we examined whether GPR43 directly suppresses insulin
signalling. Acetate significantly promoted phosphorylation of
PTEN (phosphatase and tensin homologue), a negative regulator
of insulin/PI3K signalling35, and the effect was effectively blocked
by treatment with Go6983 and PTX (Fig. 5e). In addition, acetate-
mediated suppression of insulin-induced Akt phosphorylation
was effectively blocked by treatment with bpV(pic), a PTEN
inhibitor (Fig. 5f). PKC-dependent phosphorylation of liver
kinase B1 (LKB1) is reported to promote PTEN phosphory-
lation36. Acetate significantly promoted phosphorylation of LKB1
with or without insulin, and the effect was effectively blocked by
treatment with Go6983 and PTX (Supplementary Fig. S4f). On
the other hand, acetate had no effect on insulin receptor sub-
strate1, an insulin signalling adaptor protein35) phosphorylation
(Supplementary Fig. S4g). In addition, acetate significantly
suppressed epidermal growth factor-induced Akt phosphory-







































































































































































































































































































































































































































































































Figure 3 | Adipose tissue-specific Gpr43 transgenic mice are lean. (a) Subcutaneous WATand interscapular BATof littermates (P1) were stained with oil
red O. Scale bar: 5mm (upper), 100mm (lower). Body weight changes (b, n¼6–8) and fat mass (c, n¼6, 5). Scale bar, 1 cm. (d) Haematoxylin–eosin
(H&E)-stained epididymal WAT and mean area of adipocytes (n¼4, 3). Scale bar, 100mm. Expression of aP2 and Pparg mRNA (e, n¼ 6, 5) and protein
(f) in the WAT; b-actin was used as a loading control. (g) Comparison of microbial communities, as assessed by qPCR (n¼4). Faecal major SCFA (h, n¼4)
and plasma acetate (i, n¼ 5) contents in aP2-Gpr43TG mice fed an HFD (n¼4). Body weight (j) and fat mass (k) under antibiotic treatment (n¼ 7, 6).
Body weight (l) and fat mass (m) of aP2-Gpr43TGmice fed an HFD (n¼ 7). (n) Plasma glucose concentration in aP2-Gpr43TGmice fed an HFD (n¼ 6). ITT
(o) and GTT (p) in aP2-Gpr43 TG mice fed an HFD (n¼ 6, 5). (q) Euglycaemic hyperinsulinaemic clamp in aP2-Gpr43TG mice fed an HFD. Left: glucose
infusion ratio; middle: glucose disposal rate; right: hepatic glucose production suppression. Body weights; WT (44±1.3 g): aP2-Gpr43TG (33±1.1 g),
17 weeks of age (n¼6, 5). ITT (r) and GTT (s) in aP2-Gpr43TG mice fed an HFD under antibiotic treatment (n¼ 3). (t) Oil red O-stained liver and hepatic
triglyceride content in aP2-Gpr43 TG mice fed an HFD (n¼6, 4). Scale bar, 100mm. (u) Level of WAT inflammation. Merged images from WAT, costained
with anti-F4/80 (green) and anti-caveolin1 (red) antibodies (left panel). Scale bar, 100mm. Expression of F4/80 (middle panel, n¼4–5) and TNFa (right
panel, n¼4–6) mRNA in the WAT. Mice were analysed at 16 weeks of age. All data are presented as mean±s.e.m. Student’s t-test; *Po0.05; **Po0.005;
NS, not significant.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2852 ARTICLE
NATURE COMMUNICATIONS | 4:1829 | DOI: 10.1038/ncomms2852 | www.nature.com/naturecommunications 5
& 2013 Macmillan Publishers Limited. All rights reserved.
acetate or PA significantly suppressed insulin-induced glucose
uptake and LPL activation, and these inhibitory effects were
abolished by treatment of PTX (Fig. 5g,h). Thus, acetate-mediated
activation of GPR43 suppresses the bioactivity of insulin by
suppression of Akt phosphorylation via G(i/o)bg–PLC–PKC–
PTEN (Fig. 5i).
GPR43 promotes energy expenditure. We finally assessed the
effects on energy metabolism exerted by adipose GPR43. The
plasma triglyceride content in HFD-fed Gpr43 / mice was
markedly low compared with wild-type mice, whereas that in
aP2-Gpr43TG mice was markedly high (Fig. 6a). These differ-
ences were abolished under GF conditions or by treatment with
antibiotics (Supplementary Fig. S5a,b). However, the plasma free-
fatty acid (Fig. 6b), glucose (Supplementary Fig. S5c) and insulin
(Supplementary Fig. S5d) levels were comparable between wild-
type and Gpr43 / mice fed an HFD and between wild-type
and aP2-Gpr43TG mice. Hence, changes in systemic insulin
sensitivity observed in Gpr43 / and aP2-Gpr43TG mice are
not due to abnormal secretion of insulin. These results suggested
that lipids and glucose were not taken up into adipose tissues and
were instead consumed by other tissues. As expected, the
expression of energy expenditure-, glycolysis- and b-oxidation-
related genes were increased, while the expression of gluconeo-
genesis-related genes were decreased in the muscles, but not the
liver of aP2-Gpr43TG mice (Fig. 6c; Supplementary Fig. S5e). To
assess the energy expenditure and substrate utilization, we per-
formed indirect calorimetry of wild-type and mutant mice. The
Gpr43 / mice showed decreased energy expenditure com-
pared with wild-type mice fed an HFD (Fig. 6d), although both
groups of mice showed similar locomotor activity (Fig. 6e). In
contrast, aP2-Gpr43TG mice showed an increased energy
expenditure compared with wild-type mice during all phases
(Fig. 6g), although both groups of mice showed similar levels of
locomotor activity during the light phase (Fig. 6h). Moreover,
interestingly, although Gpr43 / mice showed obesity and
aP2-Gpr43TG mice showed leaness compared with wild-type
mice fed an HFD, the respiratory exchange ratio (RER) was
higher in Gpr43 / and lower in aP2-Gpr43TG mice than in
wild-type mice (Fig. 6f,i). The RER is reduced because of pre-
ferential utilization of fat during obesity37. Collectively, our
results indicated that GPR43 activation promoted energy
expenditure and permitted the preferential utilization of fat as a
fuel through suppression of fat accumulation by inhibition of
adipose tissue-specific insulin signalling.
Discussion
SCFAs, including acetate, act as ligands for GPR43 and are
produced by gut microbiota12. Under HFD-fed conditions, faecal
SCFA and plasma acetate contents in HFD-fed mice significantly
decreased compared with those in NC-fed mice (Supplementary
Fig. S2a,b). This is presumably due the replacement of carbohydrate
with fat in the HFD, which reduced SCFA production by gut
microbiota (Supplementary Table S1). However, Gpr43 expression
was markedly higher (approximately twice) in the WAT of HFD-
fed mice as compared with NC-fed mice (Fig. 1e). This indicates
that although there was a decrease of endogenous SCFA ligands, the
increase of GPR43 expression in adipose tissue contributed to the
dramatic phenotype in Gpr43 / mice, which is further
exacerbated by the HFD-induced metabolic phenotype.
P-Akt
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Figure 4 | GPR43 suppresses insulin signalling in the adipose tissues but not in muscles or liver. Insulin-stimulated Akt phosphorylation of Ser473 in
the WAT (a, n¼ 3), muscles (b, n¼4) and liver (c, n¼ 3) of aP2-Gpr43TG mice fed an HFD after 6 h of fasting. (d–f) Inhibitory effects of acetate on
insulin signalling (1 g kg 1, i.p.). After pretreatment with acetate for 40min, a bolus of insulin (0.15U kg 1) with or without acetate (1 g kg 1) was
administered intraperitoneally. Akt phosphorylation of Ser473 in the WAT (d, n¼ 3), muscles (e, n¼ 3) and liver (f, n¼ 3) of Gpr43 / mice after
6 h of fasting. (g, h) Effect of acetate on glucose uptake in MEF-derived adipocytes from Gpr43 / or aP2-Gpr43TG mice (n¼4, respectively). (i, j)
Effect of acetate on the fatty acid uptake in MEF-derived adipocytes from Gpr43 / or aP2-Gpr43TG mice (n¼8–15). LPL activity in the WAT
(k, n¼4–5) and the muscles (l, n¼ 3–5) of Gpr43 / or aP2-Gpr43TG mice (n¼ 3–4). (m) LPL activity of Gpr43 / mice fed an HFD under GF
conditions (n¼4, 6) or aP2-Gpr43TG mice treated with antibiotics (n¼ 7, 6). All mice were analysed at 15–16 weeks of age. All data are presented as
mean±s.e.m. analysis of variance followed by Tukey–Kramer’s post hoc test (a–j) and Student’s t-test (k–m); *Po0.05; **Po0.005; NS, not significant.
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Figure 5 | GPR43 suppresses insulin signalling via G(i/o)bc-PLC–PKC–PTEN signalling. (a) Inhibitory effects of GPR43 agonists (10mM acetate and 10mM
PA) and a GPR41 agonist (10mM cyclopropanecarboxylic acid (CPC)) on insulin-induced Akt phosphorylation (n¼ 3). PA, phenylacetamide. (b) Effects of Gi/o
signalling inhibition on suppression of insulin-induced Akt phosphorylation by acetate (n¼ 3). (c) Effects of Gq signalling inhibition using siRNA (no. 1) on
suppression of insulin-induced Akt phosphorylation by acetate (n¼ 3). (d) Effects of Gbg signalling inhibition on suppression of insulin-induced Akt
phosphorylation by acetate (n¼ 3). (e) Effects of GPR43 stimulation on PTEN phosphorylation (n¼ 3). (f) Effects of PTEN signalling inhibition on suppression of
insulin-induced Akt phosphorylation by acetate (n¼ 3). Cells were stimulated with insulin (3mgml 1) in the presence of acetate (10mM) and bpV(pic) (1mM) for
5min after pretreatment with acetate for 2h. (g) Effect of GPR43 agonists (10mM acetate and 10mM PA) on insulin-induced glucose uptake (n¼4). (h) Effect of
acetate on insulin-induced LPL activity (n¼4). Cells were stimulated with insulin (3mgml 1) in the presence of acetate (10mM) and inhibitor for 30min after
pretreatment with acetate for 2h and PTX (1mgml 1) for 4h. In all experiments, cells were stimulated with insulin (3mgml 1) in the presence of GPR43 agonist
(10mM acetate, 10mM PA, or 10mM CPC) for 5min after pretreatment with GPR43 agonists for 2h, Gallein (10mM), NF023 (10mM), PTX (1mgml 1), U73122
(1mM), Go6983 (10mM),or U0126 (10mM) for 4h. All experiments were performed by using 3T3-L1-derived adipocytes (a–f, h) and MEF-derived adipocytes (g).
All data are presented as mean±s.e.m. analysis of variance followed by Tukey–Kramer’s post hoc test; *Po0.05; **Po0.005; NS, not significant. (i) Schematic
diagram of the mechanism for GPR43-mediated suppression of fat accumulation. Novel GPR43 signalling events in adipocytes are shown in red.
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GPR43 promotes leptin secretion and adipogenesis, and
inhibits lipolysis in vitro19,22–24. However, our studies, using
Gpr43 / mice and aP2-Gpr43TG mice, showed that
adipogenesis was comparable in wild-type, Gpr43 / and
aP2-Gpr43TG mice at the P1. Moreover, the plasma leptin levels
were comparable in wild-type and Gpr43 / mice. In contrast,
the plasma leptin level in aP2-Gpr43TG mice was lower than in
wild-type mice at the adult stage. These results suggested that the
in vitro experiments did not correctly reflect the physiological
conditions in vivo. Furthermore, the in vivo experiments showed
that the inhibition of lipolysis by GPR43 activation decreased the
plasma free-fatty acid level, and the response abolished in
Gpr43 / mice23. These responses may be explained by the
suppression of fat intake in the WAT via inhibition of insulin
signalling but not lipolysis. Hence, by integrating the function of
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Figure 6 | GPR43 promotes energy expenditure by increasing the consumption of lipids. Biochemical analysis of plasma obtained from Gpr43 /
mice on an HFD as well as aP2-Gpr43TG mice: triglycerides (a, n¼ 6–7); free fatty acids (b, n¼ 5–9). (c) mRNA levels of genes involved in energy
expenditure (Pgc1a), gluconeogenesis (Pepck), glycolysis (Hk1, Pkm2, and Hk2) and b-oxidation (Cpt1b and Cpt2) in the muscles of aP2-Gpr43TG mice
on an HFD (n¼4). (d) Energy expenditure of Gpr43 / mice on an HFD (n¼ 7). (e) Total activity in Gpr43 / mice fed an HFD (n¼ 5, 3).
(f) RER of Gpr43 / mice fed an HFD (n¼ 7). (g) Energy expenditure of aP2-Gpr43TG mice (n¼ 7). (h) Total activity in aP2-Gpr43TG mice (n¼ 5, 4).
(i) RER of aP2-Gpr43TG mice (n¼ 7). All mice were analysed at 16 weeks of age. All data are presented as mean±s.e.m. Student’s t-test; *Po0.05;
**Po0.005; NS, not significant.
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uptake and lipid uptake, our current study clarified that GPR43
activation leads to the suppression of insulin signalling and
thereby prevents energy accumulation.
Recently, some controversy appeared concerning the role of
GPR43 in the regulation of the energy balance in vivo. One study
showed that activation of GPR43 enhanced insulin sensitivity by
promoting GLP-1 secretion in the gut26. On the other hand,
GPR43 deficiency also improved insulin sensitivity and protected
against HFD-induced obesity and dyslipideamia via increased
energy expenditure at older ages (7–8 months of age) but an
otherwise unclear mechanism25. Our results support the former
study as our GPR43-deficient mice exhibited obesity and
impaired systemic insulin sensitivity, whereas our aP2-Gpr43TG
mice exhibited leanness and enhanced systemic insulin sensitivity.
In the adipose tissue, in particular, aP2-Gpr43TG reflected the
phenotype of Gpr43 / mice, suggesting that lipid metabolism
and fat accumulation in the adipose tissue are modulated by
adipose-expressed GPR43. We also confirmed the decrease and
increase in systemic insulin sensitivity by insulin clamp test in
HFD-fed Gpr43 / mice (Fig. 2i) and aP2-Gpr43TG mice
(Fig. 3q), respectively. Moreover, other group reported that
resistant starch supplementation leads to an increase of SCFAs,
and systemic and muscle insulin sensitivity, although systemic
FFA concentrations were not altered and LPL activity was
decreased38. Hence, this report also supports Tolhurst et al.26 and
our results. In addition, the differences between the three
knockout models, including ours, may reflect differences in the
genetic backgrounds or the variation in the gut microbiota
composition under different environments. Hence, we further
examined whether the difference of genetic backgrounds of each
mice (Bjursell et al.: C57BL/6 mice, our study: 129/SvEv mice)
and the rearing environments influence to the difference of
phenotype. At first, we backcrossed 129 background Gpr43 /
mice into C57B/6J (more than 10 times). The difference of body
weight between B6 backcrossed Gpr43 / and wild-type mice
were attenuated compared with that of the 129 background.
Nevertheless, B6 backcrossed Gpr43 / mice also exhibited
tendency of increase of body weight (Supplementary Fig. S6c).
Next, we examined SCFAs production in mice under different
environment, namely, mice housed in shoebox-style cages
(CONV conditions), and mice housed in cages in an isolation
rack ventilated with sterilized air from the backside of each rack
(specific pathogen-free conditions; SPF), because microbiota
community under CONV condition remarkably differ from that
under SPF condition39. Interestingly, faecal SCFAs contents and
plasma acetate under CONV condition were significantly higher
than that under SPF condition (Supplementary Fig. S6d,e),
presumably for change of gut microbiota composition by
different environment. Hence, GPR43 may be activated much
more under our experimental environments, because all in vivo
experiments in this study performed under CONV condition.
Moreover, although weight gain of B6 mice had no difference
between CONV and SPF condition, weight gain of 129 mice
under CONV condition were significantly suppressed compared
with that under the SPF condition (Supplementary Fig. 6f). These
results indicate that intensity of the phenotype maybe influenced
by the difference of environment and strain.
Although GPR43 is a Gi/o- and Gq-dual-coupled GPCR18,19,
recent studies have shown that all GPR43 functions are mediated
by Gi/o; no functions involving Gq have been reported for GPR43
in adipose tissues24,25. Only in the intestine, GPR43 has been
reported to promote GLP-1 secretion in L cells via the Gq
protein27. Our study also showed that GPR43 signalling in WAT
is mediated by Gi/o but not Gq. Hence, GPR43 may interact with
only Gi/o in the WAT. Moreover, our results showed that
GPR43 suppresses Akt phosphorylation by activating PTEN via
G(i/o)bg–PLC–PKC signalling and thereby inhibits fat
accumulation in WAT. We also showed that GPR43 was
abundantly expressed in the WAT but was barely expressed in
the BAT, muscles and liver, where they acted as an insulin
effectors (Fig. 1a,b). Although GPR43 suppress insulin signalling
in WAT (Fig. 4), ITT and glucose clamp test revealed that
systemic insulin sensitivity was impaired in Gpr43 / mice
and enhanced in aP2-Gpr43TG mice (Figs 2g,i and 3o,q). Glucose
clamp test further suggested that adipose GPR43 improves insulin
sensitivity in other tissues such as liver and muscle. HGP
suppression (Figs 2i and 3q) demonstrated the hepatic insulin
resistance, and the decreased Rd (Figs 2i and 3q) strongly
suggested insulin resistance in muscle, because 70–80% of total
body insulin-stimulated glucose disposal is accounted for by
skeletal muscle glucose uptake40. Moreover, energy expenditure-
and glycolysis-related genes in muscle of aP2-Gpr43TG mice
increased (Fig. 6c). Consequently, GPR43 enhances energy
utilization in other tissues except for adipose tissues. In
addition, adipose tissue-selective knockout of the insulin
receptor in mice protects against obesity and obesity-related
glucose intolerance41. Hence, this report also supports our results
that suppression of adipose insulin signalling by GPR43
activation leads to prevention of obesity and improves systemic
insulin sensitivity.
SCFAs are considered to be important energy sources for the
host42,43. On the other hand, our present study revealed that
SCFAs also act as signalling molecules for maintaining energy
balance. Feeding increased the plasma glucose and lipid levels,
and excess fatty acids and glucose were stored efficiently as fat.
However, fat accumulation by excess feeding leads to obesity and
induces several metabolic disorders. Our results showed that the
plasma SCFA levels increases following a rise in plasma glucose
level during feeding. Hence, GPR43 may function as an energy
sensor to promote the utilization of excess energy in other tissue
rather than storing excess energy as fat in the adipose tissue,
thereby maintains metabolic homoeostasis. Moreover, GF
conditions and treatment with antibiotics completely abolished
the metabolic dysfunction-related phenotype in GPR43-mutant
mice, indicating that the gut microbiota is the most important
supplier of GPR43 agonists and that the functions of GPR43 are
closely linked to the gut microbiota.
In this study, we showed that SCFAs activate GPR43 to
regulate the energy uptake in WAT, which leads to the regulation
of energy expenditure in other tissues, including liver and muscle.
We also reported that GPR41, another SCFA receptor, regulates
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GPR43 functions as sensor for excessive dietary energy
Figure 7 | Schematic model of suppression of fat accumulation via
GPR43. After feeding, SCFAs, produced by microbial fermentation in the
gut, activate GPR43 in adipose tissues. SCFA-mediated GPR43 activation
suppresses insulin-mediated fat accumulation and thereby regulates the
energy balance by suppressing accumulation of excess energy and
promoting fat consumption.
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system at the level of ganglion14. These findings indicate that
SCFAs produced by gut microbiota, through activation of GPR41
and GPR43, have important roles in recognition of postprandial
nutrient excess and orchestration of energy expenditure to
maintain energy homoeostasis (Fig. 7). In addition, the results
obtained in our GPR43-overexpression mouse model indicate
the possibility that overstimulation of GPR43 could be a
strategy for therapy of metabolic disorders, including obesity
and diabetes mellitus.
Methods
Animals. Mice were housed under a 12-h light–dark cycle and given NC
(MF, Oriental Yeast Co.). For HFD studies, 4-week-old male mice were placed on a
58Y1 diet (PMI Nutrition International) for 12 weeks. The composition of
the diets is given in Supplementary Table S1. All experimental procedures
involving mice were performed according to protocols approved by the relevant
Animal Ethics Committees. Gpr43 / mice from a 129/Sv background and
aP2-Gpr43TG mice (Acc. No. CDB0480T, http://www.cdb.riken.jp/arg/
TG%20mutant%20mice%20list.html) from a C57BL/6 background were generated.
GF mice were obtained from CLEA Japan Inc. (Tokyo, Japan) and bred in the
Central Institute For Experimental Animals (Kanagawa, Japan). Surveillance for
bacterial contamination was performed by periodic bacteriological examination
of faeces throughout the experiments. For microbiota transplantation, faecal
contents were pooled from four age- and gender-matched wild-type CONV
mice. Faecal extracts were suspended in PBS and then administered. For
antibiotic treatment, 4-week-old mice were treated with ampicillin (1.0mgml 1)
and neomycin (0.5mgml 1) in drinking water for 12 weeks28. For acetate
administration, 4-week-old mice were treated with sodium acetate (150mM)
in drinking water for 12 weeks20.
In situ hybridization. Mouse embryos were frozen in optimum cutting tempera-
ture compound (Sakura Finetech), and 18-mm sections were cut using a cryostat
and stored at  80 C until hybridization. Mouse and human antisense Gpr43
RNA probes were transcribed using T7 RNA polymerase with uridine 50-a-[35S]-
thio-triphosphate (Perkin Elmer). Sections were examined as described14, and
counterstained with haematoxylin–eosin and oil red O (Sigma) for liquid
deposition.
RNA isolation and real-time quantitative RT-PCR. Total RNA was extracted
using the RNeasy Mini Kit (Qiagen) and ISOGEN (WAKO). Complementary
DNAs were transcribed using RNAs as templates with Moloney murine leukaemia
virus reverse transcriptase (Invitrogen). cDNAs were amplified by PCR with Taq
DNA polymerase (TaKaRa) using the primers listed in Supplementary Table S2.
Real-time quantitative RT-PCR (qRT-PCR) analyses were performed using DNA
Engine Opticon-2 (MJ Research) as described14. The expression was quantified in
duplicate.
Quantification of faecal microbiota by qRT-PCR. DNA was extracted from
frozen extruded faecal contents using the QIAamp DNA Stool Mini Kit (Qiagen)
under modified manufacturer instructions. Briefly, frozen faeces was heated at
65 C for overnight. Approximately 220mg of dry stool samples were homogenized
and heated at 95 C for 5min. After incubation with an Inhibit Ex Tablet (Qiagen),
the lysates were treated with proteinase K and buffer AL at 70 C for 10min. DNA
was purified using a column provided in the kit44. DNA was then quantified as
described45,46 using the primers listed in Supplementary Table S3.
Histology. Adipose tissues were fixed in 10% neutral-buffered formalin,
embedded in paraffin and sectioned (5 mm). Haematoxylin–eosin staining was
performed using the standard techniques. To measure the diameter of the adipo-
cytes, the diameters of 100 cells from five sections from each group were measured
using NIH IMAGE J. More than 10 fields were examined, and the results were
expressed as the average. Liver tissues were embedded, frozen and sectioned
(16 mm). The sections were stained with oil red O (Sigma) for lipid deposition
as described47. Immunohistochemstry was performed by using antibodies
against F4/80 (Abcam; rat, 1:1,000) and Caveolin1 (BD Biosciences; mouse, 1:200)
as described48.
Triglyceride content assay. The liver was homogenized with acetic acid (0.5M)/
methanol/chloroform at relative proportions of 1/2.5/1.25 (v/v/v). The mixture was
shaken, and 1.25 volumes of chloroform were added. The mixture was shaken
overnight and 1.25 volumes of 0.5M acetic acid was added. After centrifugation at
1,500 g for 10min, the organic layer was collected, dried and resuspended in 100%
isopropyl alcohol. Measurements were conducted using the Triglyceride E-test
(Wako, Japan) as described47.
GTT and ITTs. For GTT, 24-h-fasted mice were given 1.5mg of glucose
per gram of body weight intraperitoneally (i.p.). For ITT, 3-h-fasted mice
were given human insulin (0.75mUg 1, i.p., Sigma). The plasma glucose con-
centration was monitored before injection and at 15, 30, 60, 90 and 120min after
injection.
Hyperinsulinaemic euglycaemic clamp. Hyperinsulinaemic euglycaemic
clamp studies were performed after 4–6 days of recovering from cannulization as
described previously with minor modification49. During clamp studies,
human insulin was infused at 3mUkg 1min 1 into mice, with variable amounts
of 40% glucose solution to maintain a blood glucose level of 90–120mg dl 1.
The blood glucose was measured every 10min. GIR and endogenous glucose
production were measured between 90 and 120min after the initiation of
insulin infusion.
Assay of biochemical responses to insulin stimulation. Insulin (0.15U kg 1,
Sigma) was injected i.p. After 5min, liver, skeletal muscle or WAT were
dissected and immediately frozen in liquid nitrogen. Immunoblot analysis was
performed as described47.
Adipocyte culture. MEFs and 3T3-L1 pre-adipocytes (ATCC) were cultured at
37 C in a-MEM (for MEFs) or Dulbecco’s modified Eagle’s medium (DMEM,
for 3T3-L1) containing 1% penicillin–streptomycin solution (Gibco) with 10%
fetal bovine serum (FBS). Two days after confluence, the medium was replaced
with a-MEM or DMEM containing 10% FBS and inducers (0.25 mM dex-
amethasone, 10 mgml 1 insulin, and 0.5mM 3-isobutyl-1-methylxanthine) as
well as pioglitazone (10mM) for 2 days. The medium was then changed to DMEM
supplemented with 10% FBS, 10 mgml 1 insulin and 10mM pioglitazone, and then
incubated for 2 days. After 5 days, the differentiated adipocytes were used for
experiments50.
Glucose uptake assay. The epididymal fat pads were minced and washed
with KRBH (Krebs-Ringer bicarbonate solution buffered with 30mM HEPES,
pH 7.4, containing 2.5mM glucose and 1% (w/v) fatty-acid-free bovine serum
albumin (Sigma), and were incubated with collagenase type 2 (1mgml 1, Sigma)
at 37 C. After 15min, the content was filtered and washed with KRBH without
glucose. The floating cells or MEF-derived adipocytes were incubated with KRBH
without glucose for 30min or 3 h, respectively, with or without acetate (10mM).
After incubation with insulin (3 mgml 1) for 20min at 37 C, 0.1mM
2-deoxyglucose (Sigma) and 1 mCi [3H]-2-deoxyglucose (Moravek Biochemicals)
were added, and incubated for 10min at 37 C. The adipocytes were washed
three times with ice-cold KRBH with 2.5mM glucose, and the level of radioactivity
was counted51.
Fatty acid uptake assay. MEF-derived adipocytes were plated into 96-well black-
well, clear-bottom plates. Cells were serum deprived for 1 h, with or without acetate
(10mM), before treatment with insulin (3 mgml 1) for 30min. QBT Fatty Acid
Uptake solution (Molecular Probes) was then added. After 1 h, the fluorescence
intensity was measured using a Wallac 1420 ARVOsx (Perkin Elmer).
Biochemical analyses. The plasma glucose concentrations was measured
using a One Touch Ultra (LifeScan). Measurements of the plasma FFA and
triglyceride concentration was performed in SRL Inc. The plasma acetate
concentration was measured using F-kit acetate (Boehringer Mannheim).
Measurements of faecal SCFAs by ion chromatography (IC) were entrusted to
the Kyoto Institute of Nutrition and Pathology Inc.
LPL activity assay. Tissues were homogenized in 0.1M sodium phosphate,
pH 7.4, and centrifuged at 10,000 g for 20min at 4 C. The LPL activity was
measured by using an LPL assay kit (Roar Biomedicals). For differentiated 3T3-L1
cells, cells were pretreated with PTX (1 mgml 1) in complete medium for 2 h.
Adenosine A1 receptor, a Gi/o-coupled GPCR, is constitutively activated by
endogenous adenosine32. Hence, the cells were pretreated with 1% BSA (fatty acids
free) and adenosine deaminase (1Uml 1) for 2 h to suppress increase of LPL
activity by PTX-induced suppression of this receptor. Next, the cells were serum
deprived for 2 h with or without acetate (10mM), and PTX (1 mgml 1) before
treatment with insulin (3 mgml 1) for 30min, followed by treatment with heparin
(100U/ml 1, Ajinomoto) for 10min. The culture medium was then removed and
assayed.
Indirect calorimetry. The oxygen consumption (VO2) and RER were determined
with an O2/CO2 metabolic measuring system (Model MK-5000, Muromachi Kikai)
at 24 C as described14. VO2 was expressed as the volume of O2 consumed per
kilogram of lean body mass weight per minute. The energy expenditure was
calculated as the product of the calorific value of oxygen (3.815þ 1.232RER) and
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VO247. The locomotor activity was measured by using an infrared-ray passive
sensor system (Supermex, Muromachi Kikai Co.).
Knockdown by siRNA. Adipocytes were transfected with 40 nM siRNA shown in
Supplementary Table S4 (Stealth Select RNAi, Invitrogen) using the Lipofectamine
RNAiMAX transfection reagent (Invitrogen) as described14.
Western blotting. Cells were lysed in TNE buffer. Tissues were homogenized in
0.1M sodium phosphate buffer, pH 7.4, and centrifuged at 10,000 g for 20min at
4 C. The supernatants were analysed by western blotting using antibodies tar-
geting Akt, phosphorylated Akt (Ser473), ERK1/2, phosphorylated ERK1/2, aP2,
PPARg, phosphorylated PTEN (Ser380/Thr382/383), PTEN, phosphorylated LKB1
(Ser428), LKB1 (Cell signaling; rabbit, 1:1,000), Gq (Santa Cruz; rabbit, 1:200) and
b-actin (Sigma; mouse, 1:1,000). The immunoreactive bands were visualized as
previously described14.
Statistical analyses. Values are presented as the mean±s.e.m. Differences
between groups were examined for statistical significance using Student’s t-test
(two groups) or analysis of variance (Z3 groups). P-valueso0.05 were considered
statistically significant.
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